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5Abstract
Background: Although tumor necrosis factor (TNF) inhibitors are used to treat chronic 
inflammatory diseases, there is little information about how long-term inhibition of TNF affects 
the homeostatic functions that TNF maintains in the intact CNS. 
Materials and methods: To assess whether developmental TNF deficiency causes alterations in the 
naïve CNS, we estimated the number of proliferating cells, microglia, and neurons in the 
developing neocortex of E13.5, P7 and adult TNF knock out (TNF-/-) mice and wildtype (WT) 
littermates. We also measured changes in gene and protein expression and monoamine levels in 
adult WT and TNF-/- mice. To evaluate long-term effects of TNF inhibitors, we treated healthy adult 
C57BL/6 mice with either saline, the selective soluble TNF inhibitor XPro1595, or the nonselective 
TNF inhibitor etanercept. We estimated changes in cell number and protein expression after two 
months of treatment. We assessed the effects of TNF deficiency on cognition by testing adult WT 
and TNF-/- mice and mice treated with saline, XPro1595, or etanercept with specific behavioral 
tasks. 
Results: TNF deficiency decreased the number of proliferating cells and microglia and increased 
the number of neurons. At the same time, TNF deficiency decreased the expression of WNT 
signaling-related proteins, specifically Collagen Triple Helix Repeat Containing 1 (CTHRC1) and 
Frizzled receptor 6 (FZD6). In contrast to XPro1595, long-term inhibition of TNF with etanercept in 
adult C57BL/6 mice decreased the number of BrdU+ cells in the granule cell layer of the dentate 
gyrus. Etanercept, but not XPro1595, also impaired spatial learning and memory in the Barnes 
maze memory test. 
Conclusion: TNF deficiency impacts the organization of neurogenic zones and alters the cell 
composition in brain. Long-term inhibition of TNF with the nonselective TNF inhibitor etanercept, 
6but not the soluble TNF inhibitor XPro1595, decreases neurogenesis in the adult mouse 
hippocampus and impairs learning and memory after two months of treatment.
71. Background
The cytokine tumor necrosis factor (TNF) plays important roles in the homeostasis of the healthy 
central nervous system (CNS), as well as in pathological inflammatory states. TNF is expressed as a 
transmembrane form (tmTNF) that can be cleaved into a soluble form (solTNF) by the TNF alpha 
converting enzyme (TACE/ADAM17) (Black et al., 1997). Signal transduction of solTNF mainly 
occurs through TNF receptor 1 (TNFR1), while tmTNF can activate both TNFR1 and TNFR2 (Grell et 
al., 1995; Grell et al., 1998). TNF signaling has been associated with neuron maturation in the 
dentate gyrus and the shaping of dendritic trees in CA1 and CA3 hippocampal regions in early 
development (Golan et al., 2004a). Signaling through TNFR1 can decrease neural progenitor 
proliferation in the granule cell layer of the dentate gyrus, increase apoptosis of neural stem cells, 
and disrupt their differentiation into neurons (Hofer et al., 2011; Iosif et al., 2006; Keohane et al., 
2010; Seguin et al., 2009). In contrast, lack of TNF receptor 2 (TNFR2, p75TNFR) can affect the 
formation of new neurons (Chen and Palmer, 2013), indicating that TNFR2 is important for 
neurogenesis. Although neurogenesis declines with age, it continues into adulthood in rodents 
(Bordiuk et al., 2014) and also moderately in humans (Altman and Das, 1965; Eriksson et al., 1998; 
Spalding et al., 2013). 
In the healthy CNS, TNF is produced by microglia, astrocytes, and neurons (reviewed by (McCoy 
and Tansey, 2008)), while in inflammation it is mainly produced by microglia (reviewed in 
(Lambertsen et al., 2018)). Surveilling microglia are involved in clearing apoptotic newborn 
neurons, synaptic pruning, and enhancing neurogenesis (Batchelor et al., 2002; Paolicelli et al., 
2011; Ribeiro Xavier et al., 2015; Schafer et al., 2012; Shigemoto-Mogami et al., 2014). On the 
other hand, activated microglia can impair integration of newborn neurons into the neural 
network (Belarbi et al., 2012), and in redundant inflammatory conditions they can exaggerate the 
8death of newborn neurons by secreting neurotoxic proinflammatory cytokines like TNF, interleukin 
(IL)-6, and IL-1β (Cacci et al., 2005; Ekdahl et al., 2003; Monje et al., 2003). It is well established, 
however, that microglia can benefit neuron proliferation in both intact and inflamed CNS 
(Bachstetter et al., 2011; Butovsky et al., 2005; Ekdahl, 2012; Ekdahl et al., 2009; Hanisch and 
Kettenmann, 2007; Shigemoto-Mogami et al., 2014; Vukovic et al., 2012; Walton et al., 2006; Ziv 
et al., 2006; Aarum et al., 2003).
TNF signaling regulates cognition in adulthood by interfering with memory consolidation (Golan et 
al., 2004a). Elevated TNF levels cause depressive-like behavior in rodents while inhibition of solTNF 
with the selective solTNF inhibitor XPro1595 reverses the effects (Bedrosian et al., 2013; Kaster et 
al., 2012). Also, inhibition of TNF has been shown to relieve fatigue and symptoms of depression 
associated with chronic inflammatory diseases (Tyring et al., 2006). 
The TNF inhibitors currently in use to treat chronic inflammatory diseases block both solTNF and 
tmTNF. Their beneficial effects are hampered by increased risk of infections, cardiovascular 
conditions, and demyelination  (Scheinfeld, 2004). These negative side-effects have been 
associated with tmTNF inhibition as tmTNF supports secondary lymphoid structure and promotes 
the normal function of the innate immune system (Ruuls et al., 2001), just as tmTNF appears to be 
important in cardiac remodeling (Danila et al., 2008) and remyelination (Brambilla et al., 2011). 
Selective solTNF inhibitors are being extensively studied in experimental CNS pathologies to find 
safer alternatives to existing TNF inhibitors without compromising the inflammation-suppressing 
effects (Barnum et al., 2014; Brambilla et al., 2011; Cavanagh et al., 2016; Clausen et al., 2014; 
Karamita et al., 2017; MacPherson et al., 2017; Novrup et al., 2014).
WNT signaling is a key regulator of embryonic neurogenesis (Kleber and Sommer, 2004) and is the 
main pathway in adult neurogenesis, synaptogenesis (Hall et al., 2000; Lie et al., 2005; Rosso and 
9Inestrosa, 2013), and hippocampal function (Alvarez-Buylla and Lim, 2004). WNT proteins work 
through frizzled receptors (FZD) (Bhanot et al., 1996), of which FZD6 can activate the non-
canonical/planar cell polarity pathway and inhibit the canonical pathway (Golan et al., 2004b; 
Mirkovic et al., 2011). Collagen Triple Helix Repeat Containing 1 (CTHRC1) is another WNT cofactor 
protein involved in activation of the planar cell polarity pathway (Yamamoto et al., 2008). Both 
FZD6 and CTHRC1 stabilize the WNT receptor complex (Yamamoto et al., 2008).
The aim of the present study was to explore the effects of TNF deficiency in the developing and 
adult cortex and hippocampus on the organization of neurogenic zones and on memory and 
learning. We also compared the effect on learning and memory of nonselective TNF inhibition 
using etanercept versus selective solTNF inhibition using XPro1595.
2. Materials and methods
2.1 Animals
TNF-/- mice, on a C57BL/6 background (Pasparakis et al., 1996), were obtained from the Jackson 
Laboratory and transferred to the Biomedical Laboratory, University of Southern Denmark where 
they were kept as a colony. Experiments were performed using embryonic day 13.5 (E13.5), 
postnatal day 7 (P7), and male 2- or 4-month-old (adult) TNF-/- mice and wildtype (WT) littermates, 
as well as 2-month-old C57BL/6 male mice (Taconic Ltd., Ry, Denmark), in the studies with TNF 
inhibitor treatments. The animals were housed in diurnal lighting conditions with food and water 
available ad libitum. Animal experiments were performed according to the guidelines and 
regulations approved by the Danish Animal Ethical Committee (numbers 2011/561-1950 and 
2013-15-2934-00924).
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2.2 Study design
We first characterized the possible effects of developmental TNF deficiency and long-term 
inhibition of TNF in adulthood on gene and protein expression, monoamine levels, neurogenesis, 
and cell composition in the brain, and on the function and permeability of the blood-brain barrier 
(BBB). We then investigated the effect of TNF deficiency on cognitive functions. 
2.3 Pharmacological treatment
Saline, XPro1595 (10 mg/kg) (Xencor Inc., Monrovia, CA) (Steed et al., 2003), or etanercept (10 
mg/kg) (Enbrel, Amgen-Wyeth, Thousand Oaks, CA, USA) was administered subcutaneously (s.c.) 
in the 2-month-old C57BL/6 mice every third day for two months. One day after the first s.c. 
injection of saline, XPro1595, or etanercept, a single injection of 5’-Bromo-2’-Deoxyuridine (BrdU) 
(50 mg/kg, Sigma-Aldrich, Søborg, Denmark) was administered intraperitoneally (i.p.). Seven (7) 
weeks later, just prior to the Barnes maze test and one week prior to euthanization, mice were 
administered i.p. with a single injection of 5-ethynyl-2'-deoxyuridine (EdU) (50 mg/kg, InVitrogen, 
Tåstrup, Denmark). Mice were weighed every third day, starting on the day of the first saline, 
XPro1595, or etanercept injection. 
2.4 Tissue processing
E13.5 WT and TNF-/- fetuses were obtained after cervical dislocation of the dams. Whole fetal 
brains were fixed in Bouin’s solution (Sigma-Aldrich, Denmark) before being rinsed, dehydrated in 
increasing concentrations of ethanol, and embedded in paraffin (Stolp et al., 2011). Coronal brain 
sections of 10 m thicknesses were cut on a microtome.
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P7 and adult mice were overdosed i.p. with pentobarbital (200 mg/ml) containing 
lidocainhydrochlorid (20 mg/ml) (Glostrup Apotek, Glostrup, Denmark) and perfused through the 
left ventricle with ice-cold phosphate-buffered saline (PBS, pH 7.4, Sigma-Aldrich) followed by ice-
cold 4% paraformaldehyde (PFA, pH 7.4, Sigma-Aldrich). Brains from P7 mice were paraffin-
embedded and cut into 6 parallel series of 30 m thick microtome sections. Brains from adult mice 
were cut on a vibratome into 60 µm free-floating coronal sections in 6 parallel series and stored in 
de Olmos cryoprotectant solution containing 1% polyvinylpyrrolidone and 20% sucrose diluted in a 
mixture of 30% ethylene glycol and PBS and stored in a freezer at -12°C until further processing.
PBS-perfused brains of 2-month-old naïve WT and TNF-/- male mice were dissected and processed 
for monoamine analysis or microarray and real-time reverse transcriptase-quantitative 
polymerase chain reaction (RT-qPCR) analysis. PBS-perfused brains from 4-month-old WT and TNF-
/- mice and saline-, XPro1595-, and etanercept-treated C57BL/6 mice were divided into left and 
right hemispheres and stored at -80°C before processing for Western blotting. Blood from mice 
treated with saline or TNF inhibitors was collected in EDTA-coated Eppendorf tubes and 
centrifuged 20 min at 3,000g, 4°C. Plasma was stored at -80°C until processing for Multiplex 
cytokine assay (Mesoscale Discovery, Rockville, MD, USA) as previously described (Madsen et al., 
2016).  
2.5 Microarray procedure and analysis
Two-months old, adult male WT and TNF-/- brain lysates were used for RNA isolation. Isolated RNA 
was quality assessed using the Agilent RNA 6000 Nano Kit (Agilent Technologies, Santa Clara, CA, 
USA) with an Agilent 2100 bioanalyzer (Agilent Technologies). Isolated RNA was hybridized to the 
Affymetrix GeneChip Mouse Gene 1.0 ST Array according to the manufactorer protocol (Thermo 
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Fisher Scientific, Waltham, MA, USA). We used the Significance Analysis of Microarray (SAM) 
method to identify probe sets with target in transcripts that were significantly differentially 
expressed between WT and TNF-/- mice (Tusher et al., 2001). SAM analysis was performed using 
MultiExperimentViewer Software v. 4.5.1. (Dana-Farber Cancer Institute, Boston, MA, USA), 70 
unique permutations and an s0 value selected by Tusher’s method (Saeed et al., 2006; Saeed et 
al., 2003; Tusher et al., 2001). A false discovery rate (FDR) < 5% was considered evidence of 
statistical significance. Significant genes were analyzed for Gene Ontology (GO) terms and Kyoto 
Encyclopaedia of Genes and Genomes (KEGG) pathways related to neurogenesis and inflammation 
in http://pantherdb.org (version 13.1), string-db.org (version 10.5), and http://www.genome.jp/. 
Primary microarray data were submitted to the public database at the GEO website 
(http://www.ncbi. nih.gov/geo; record number: GSE134178).
2.6 Real-time RT-qPCR
Real-time RT-qPCR was performed for Catechol-O-methyl transferase (Comt1), Arachidonate 8-
lipoxygenase (Alox-8), Lipoprotein lipase (Lpl), c-Fos (Cfos), TNF (Tnf), TNFR1 (Tnfrsf1a), TNFR2 
(Tnfrsf1b), IL-1β (il1b), IL-1α (il1a), IL-1 receptor antagonist (IL-1Ra, Il1rn), 5-Hydroxy tryptamine 
transporter (5-HTT, Scl6a4), 5-Hydroxytryptamine receptor 2A (Htr2a), CD11b (Itgam), 
Nicotinamide nucleotide transhydrogenase (Nnt), Inositol-trisphosphate 3-kinase A (Itpka), 
Tachykinin receptor 3 (Tacr3), Synuclein alpha (Snca), Parkin RBR E3 Ubiquitin Protein Ligase 
(Park2), and Acid-sensing ion channel 1 (Asic1) using cDNA isolated from brain tissue from 2-
month old WT and TNF-/- male mice on an iCycler (Bio-Rad Laboratories, Hercules, CA, USA) as 
previously described (Clausen et al., 2014; Clausen et al., 2008; Clausen et al., 2016; Lambertsen et 
al., 2007) with primer sequences found in Table 1. For Tnf, we used both no-see and see primers. 
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The no-see primer set was designed to target the Tnf gene flanking the inserted neomycin cassette 
and thus should not detect Tnf mRNA. The see Tnf primers were designed to target outside the 
neomycin cassette, resulting in expression of a non-functional Tnf mRNA (Lambertsen et al., 2009; 
Pasparakis et al., 1996). Values were normalized to hypoxanthine phosphoribosyltransferase 1 
(Hprt1) as the reference gene and calibrated to a pool of unmanipulated C57BL/6 mice 
(Lambertsen et al., 2009). Primers were designed to target exon-exon junctions whenever possible 
and were purchased from TAG Copenhagen (Copenhagen, Denmark). All samples were analyzed 
using SYBR green except for Htr2a and Slc6a4 that were analyzed using TaqMan probes. Transcript 
levels within two-fold threshold of methodological resolution were not subjected to statistical 
analysis (Meldgaard et al., 2006).
2.7 Western blotting
Brain tissue (one hemisphere) from 4-month old WT, TNF-/-, and C57BL/6 mice treated with saline, 
XPro1595, or etanercept were lysed with complete mesoscale lysis buffer (Mesoscale Discovery), 
sonicated, and centrifuged for 20 min at 14,000g, 4°C. Supernatants were collected and stored at -
80°C. Protein concentrations were determined using Micro BCA™ protein assay kit (Thermo Fisher 
Scientific) according to the manufacturer’s instructions. Protein samples (10 μg) were separated 
on SDS-PAGE 4-12% Bis-Tris- gels (Thermo Fisher Scientific) and wet transferred to an Immobilon-P 
transfer membrane (Merck Life Science, Darmstadt, Germany). The membrane was blocked using 
5% non-fat milk in 0.05M tris-buffered saline+0.05% Tween-20 (TBST, Sigma-Aldrich). Anti-CTHRC1 
antibody or anti-FZD6 antibody (Table 2) was added for overnight incubation at 4°C. Anti-actin 
antibody (Table 2) was used as a loading control. The next day, secondary horse-radish peroxidase 
(HRP)-conjugated anti-rabbit IgG or anti-mouse IgG (Table 2) was added. Membranes were 
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developed using SuperSignal™ West Dura Extended Duration Substrate (Thermo Fisher Scientific) 
and ChemiDoc™ MP Imaging System (Bio-Rad). Analysis was performed on un-manipulated images 
by measuring the intensity of the western blotting bands using Image Lab™ software (Bio-Rad) 
according to the manufacturer’s instructions. The mean sample intensity of the band of interest 
was divided by the corresponding mean loading control intensity for normalization and presented 
as relative intensity to WT for the TNF-/- mice, or relative intensity to saline for XPro1595- and 
etanercept-treated mice. 
2.8 High-performance liquid chromatography of brain monoamines
Brains from 2-months-old male WT and TNF-/- mice were dissected into ipsi- and contra-lateral 
sides of frontal cortex, occipital cortex, striatum, hippocampus, thalamus + hypothalamus, and 
cerebellum and kept on dry ice. Dissected tissue was briefly sonicated in Eppendorf tubes 
containing 200-1,000 µl (1:20 weight/volume) of ice-cold 0.1M perchloric acid (PCA) (Sigma-
Aldrich) containing antioxidants (Na2S2O5 and Na2-EDTA, Sigma-Aldrich) and centrifuged at 
20,627xg for 20 minutes at 4oC. The supernatant was used for reverse-phase high-performance 
liquid chromatography (HPLC) analysis. Levels of noradrenalin (NA), dopamine (DA), serotonin (5-
hydroxytryptamine, 5-HT), the DA metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and 
homovanillic acid (HVA), and the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA) were 
assessed by HPLC with electrochemical detection, essentially as previously described 
(Gramsbergen et al., 2002) but using a mobile phase consisting of 10% methanol (volume/volume) 
(Sigma-Aldrich), citric acid monohydrate (Sigma-Aldrich), octane-1-sulfonic acid sodium salt 
(Sigma-Aldrich), and EDTA (Sigma-Aldrich) dissolved in Milli-Q water and pH adjusted to 4.0 
(Santiago et al., 2010). The Merck-Hitachi HPLC system consisted of an L-7100 pump, an L-7200 
15
autosampler, a D-7000 interface, and an electrochemical detector with inbuilt column oven (Antec 
Leyden - DECADE, Zoeterwoude, Netherlands), connected to a computer equipped with D-7000 
version 2.0 chromatography software. The mobile phase was pumped at a flow rate of 0.9 ml/min 
through a Waters Spherisorb S5 ODS2 guard column (4.6×30 mm) and a Waters Spherisorb S3 
ODS2 cartridge analytical column (4.6×150 mm, Waters, Milford, MA, USA). A single amount of 20 
or 10 L of external standards (0.5 or 0.25 pmols) per compound was injected and peak heights 
were used to calculate the absolute amounts of the compounds of interest in the brain tissue 
samples. Calibration curves were based on peak height at 0.5 or 0.25 pmol and 0 pmol (injection 
with no compound gives no peak, thus calibration curve is forced through zero). Peak heights were 
linearly related to the amounts on column, thereby allowing calculations on the basis of a single 
amount of external standard for a particular compound. Brain tissue samples were diluted 
appropriately, so that peaks of the compounds of interest were within the detectable range. To 
allow calculation of all compounds of interest, different dilutions and multiple injections were 
necessary.  
2.9 Histology
Tissue sections from E13.5 fetuses and P7 mice were heated at 60C for 1 hour, cleared in xylene 
(VWR, Søborg, Denmark) (2x 5min), rehydrated in ethanol (2x 3 min in 99%, 1x 3 min in 96%, and 
1x 3 min in 70%), and then rinsed in running tap water followed by distilled water (dH2O). For 
hematoxylin and eosin (HE) staining, sections were placed in filtered Mayer’s hematoxylin (Sigma-
Aldrich) for 3 min, rinsed 3x in dH2O, and placed in running tap water for 10 min. Next, sections 
were rinsed in dH2O and placed in 0.2% eosin mixed 1:5 with 70% ethanol for 2 min. Sections were 
dehydrated in ethanol, cleared in xylene, mounted, and coverslipped using Depex mounting media 
(VWR). For Toluidine blue (TB) (Sigma-Aldrich) staining, sections were placed in 70% ethanol 
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overnight at room temperature. The next day, sections were rinsed 10x in dH2O, placed in TB 
solution for 3 min, rinsed 10x in dH2O, and cleared in 96% and 99% ethanol followed by xylene. 
Sections were coverslipped using Depex mounting media.
2.10 Immunohistochemistry 
One series of sections from E13.5 and P7 mice was deparaffinated and, together with one series of 
tissue sections from 2-months old WT and TNF-/- and from mice treated with saline, XPro1595 or 
etanercept, was blocked for endogenous peroxidase activity in either 0.2%, 3%, or 5% H2O2 in 
methanol, depending on the optimized staining protocol, for 30 min to 1 hour followed by 
incubation in primary antibodies overnight at 4C. All primary and secondary antibodies used for 
immunohistochemistry are listed in Table 2 along with tertiary reagents and isotype and serum 
controls. For identification of EdU+ cells, sections were stained with Click-iT™ EdU Alexa Fluor™ 
488 Imaging Kit (Thermo Fisher Scientific) according to the kit protocol. Isotype controls and IgG 
controls for polyclonal rabbit antibodies were done using comparable IgG concentrations. In 
addition, omission of primary antibodies was used as negative controls. Sections were developed 
in 3,3’-diaminobenzidine (DAB) (Sigma-Aldrich) and mounted as previously described (Lambertsen 
et al., 2011).
2.11 Cell estimate  
E13.5: We selected sections at the level of the interventricular foramina (Bregma -0.4 in the adult 
brain), corresponding to the putative somatosensory cortex. The number of proliferating cells was 
estimated by manually counting PH3+ cells on a Leica DMR200 microscope in the ventricular zone 
(VZ) and subventricular zone (SVZ). The VZ was defined as the layer of cells immediately adjacent 
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to the ventricles, while the SVZ formed a defined band between the VZ and the edge of the cortex. 
To exclude variation in VZ length due to natural size variation as a source of error, the VZ length 
was measured in ImageJ (NIH) using the ”freehand line” tool following recommendations of the 
ImageJ developers (Schneider et al., 2012). PH3 cell counts along the VZ surface were normalized 
to the length of the VZ in the dorsal cortex for each section examined resulting in a value for the 
number of cells/pixel. The number of Iba1+ microglia was counted manually with a clicker in the 
developing neocortex in three sections per animal placed immediately adjacent to those where 
analysis if PH3+ proliferating cells were carried out. Two measurements were made: the total 
number of microglia in the brain and the percentage of non-rounded microglia (i.e. ramified 
defined as cells with more than 2 lines of asymmetry). Spherical Iba1+ cells in close proximity to 
vasculature or red blood cells were assumed to be blood monocytes and were excluded from the 
count.
P7 and adult mice: The total number of cells was estimated using a BX50 microscope (Olympus, 
Ballerup, Denmark) coupled to the computer-assisted newCAST stereology system from 
Visiopharm (Hørsholm, Denmark). Cells were counted using a 100x oil lens and a counting frame of 
799.8 μm2, with step size of 400 μm (microglia and neurons) and 200 μm (Ki67+ cells) (Lyck et al., 
2007). The total number of cells was calculated using the formula: N = Q- x (1/tsf) x (1/asf) x 
(1/ssf), where Q- represents the total number of counted cells, tsf the thickness sampling 
fraction (tsf = t/h = 15.5 μm/8 μm for P7 and 20 μm/12 μm for adult mice), asf the area sampling 
fraction (a(frame)/a(step) = 799.8 μm2/160,000 μm2 in neocortex or 799.8 μm2/40,000 μm2 in 
dentate gyrus), and ssf the sections sampling fraction (ssf = 1/6). The total number of Iba1+ 
microglia, CD11b+ microglia, and TB+ neurons were estimated in the right hemisphere of 
neocortex, while the number of Ki67+ proliferating cells was estimated in the dentate gyrus of the 
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hippocampus. Estimated cell numbers were multiplied by two for P7 mice in order to take cell 
numbers in the contralateral side of the brain into account. Identification of neurons in the TB 
staining was based on the typical neuronal morphology of large cell bodies, pale nucleus 
containing one nucleolus, and cytoplasm containing Nissl substance (Lyck et al., 2007). 
In the hippocampus, the total number of BrdU+ and EdU+ cells throughout the granular cell layer of 
the dentate gyrus of mice treated with saline, XPro1595, or etanercept were counted manually 
using a 20x objective. Cells lying more than 20 m deep into the hilum were not included. All cell 
estimates were made with the observer blinded to the genotype.
2.12 Volume calculations and cell density
Photomicrographs were acquired using the 4x (E13.5) or 2x (P7) lens and 1.25 tube factor on an 
Olympus BX51 microscope fitted with an Olympus D973 camera and coupled to CellSens Software 
(Olympus). Light settings were kept constant for all pictures taken. Densitometry was performed in 
the developing neocortex from images of E13.5 tissue stained for albumin, claudin-5, and glucose 
transporter 1 (GLUT1) using Image J analysis software (NIH) as per directions of the Image J 
developers (http://rsb.info.nih.gov/ij). Briefly, all TIFF files were gray-scaled (8 bits) using Adope 
Photoshop CS5 for Mac, pictures imported into Image J and background subtracted. Each section 
was delineated using the “freehand tool” based on microscopic landmarks (Schambra et al., 1991) 
and the densitometry measured across each section was estimated using the Log10(Mean 
value/255) calculation. A mean density was found for each section and presented as relative 
density to WT. The length and area of the ganglionic eminence (GE) were estimated in HE-stained 
sections from E13.5 fetuses. The volumes of the ventricles, subependymal zone (SEZ), and cortex 
(bregma 1.70 to -0.82) were estimated in HE-stained sections from P7 mice and the density of 
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ki67+ cells was estimated in the SEZ, as described above. The neocortex was delineated as 
previously described (Lyck et al., 2007) and contained the anterior part of the agranular insular 
cortex, orbital cortex, cingulate cortex, frontal cortex, pre-limbic cortex, granular insular cortex, 
retrosplenial agranular cortex, anterior parts of retrosplenial granular cortex, entorhinal cortex, 
parietal cortex, temporal cortex, and all areas of the occipital cortex. Cortex volume was estimated 
using the principle of Cavalieri (Gundersen et al., 1988). Volumes of lateral ventricles, SEZ, and 
cortex in P7 mice were multiplied by 2 in order to take the contralateral hemisphere into account.
2.13 Behavioral tests
The behavioral battery incorporated several different types of tests conducted in the following 
order: (1) Y maze test, (2) Open field test, (3) Elevated plus maze test, and (4) Barnes maze test. 
Mice were given a least one day off between tests, which were conducted in order of least to most 
stressful to minimize effects of previous testing. All behavioral tests were performed with the 
observer blinded to the genotype or treatment.
Y maze. The Y maze was used to evaluate short-term memory and exploratory behavior in 4-
month old WT and TNF-/- mice, and in C57BL/6 mice before (at 2 months of age) and after 
treatment (at 4 months of age) with TNF inhibitors as previously described (Lambertsen et al., 
2012). In brief, each mouse was placed in the arm designated (A) of the Y-maze field. Except for 
the first two, the number of entries into each arm (A, B, C) was recorded manually over an 8 min 
period and spontaneous alternation calculated based on these numbers.
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Open field. The open field test was performed one and two months after the start of TNF inhibitor 
treatment to test anxiety and locomotor activity in C57BL/6 mice as previously described 
(Lambertsen et al., 2012). The open field test was performed using a non-transparent plastic 
square arena measuring 45 (W) x 45 (D) x 40 (H) cm. The arena was divided into three zones (wall, 
intermediate and center), and spontaneous movements in each zone were tracked using the 
SMART 3.0 Video Tracking System (Panlab Harvard Apparatus, Barcelona, Spain) connected to a 
high-resolution color video camera (SSC-DC378P, Biosite, Stockholm, Sweden). Mouse behavior 
was recorded over a 10 min period and total distance travelled (m), as well as time spent in each 
zone were automatically recorded. A center/perimeter ratio was calculated as previously 
described (Lambertsen et al., 2012). Rearing, as a measure of stereotypical mouse behavior, was 
manually recorded and expressed as total number of events.
Elevated plus maze. The elevated plus maze was used to assess anxiety-related behavior in 4-
months old WT and TNF-/- as previously described (Ellman et al., 2017). The elevated plus maze 
apparatus consisted of two open arms and two closed arms (30 cm x 5 cm). Each mouse was 
placed in the center of the maze with the head facing towards the open arm. During a 5 min test, 
the total distance travelled and the time spent in the closed and open arms were recorded using 
the SMART video tracking software (Panlab). A open/closed arm ration was calculated based on 
the times spent in each arm as a measure of anxiety-related behavior.
Barnes maze. After 7 weeks of saline, XPro1595, or etanercept treatment, C57BL/6 mice and 4-
months-old WT and TNF-/- mice were subjected to Barnes maze for assessment of long-term 
memory and spatial recognition. The test was performed according to the protocol previously 
described (Ellman et al., 2017). Mice interacted with the Barnes maze in three phases: habituation 
(1 day), training (3 days), and probe (1 day). They were housed in the behavior room during the 
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whole experiment. On the habituation day, mice were placed in the center of the maze inside a 
transparent starting cylinder (diameter: 8 cm; height: 12.5 cm) for 30 sec. Then mice were guided 
slowly by moving the cylinder towards the target hole that lead to the escape box while loud 
heavy metal music was played. After 10-15 sec, the cylinder was removed and mice were given 3 
min to independently enter through the target hole into the escape box. If they did not enter on 
their own during that time, they were gently guided. Mice were allowed to stay in the escape box 
for 1 min with the music turned off before being returned to a holding cage. In the training phase, 
mice were placed inside a non-transparent starting cylinder placed in the center of the maze for 
15 sec. At the end of the holding period, the music was started and they were allowed to explore 
the maze for 3 min. If a mouse found the escape box and entered it during that time, it was 
allowed to stay there for 1 min. If it did not find the escape box, it was gently guided towards it. 
Each mouse was provided a 20-30 min inter-trial resting period. The total number of trials each 
day was 5. On the probe day, the escape box was removed and the mice were placed inside the 
starting cylinder placed in the center of the maze for 15 sec, the music was turned on, and the 
cylinder removed. Each mouse was given 2 min to explore the maze, whereafter the mouse was 
returned to its cage. After the first 4 trials, external cues were exchanged 180° and the test was 
repeated, in order to test whether the mouse used external clues to navigate after. Measures of 
time spent in the quadrant where the escape box used to be (target quadrant) were recorded, 
along with time spent in the positive, negative and opposite quadrants. For these analyses, the 
maze was divided into quadrants of 5 holes.
2.14 Phagocytosis assay
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In order to test the effect of TNF on microglial phagocytic activity, primary microglia derived from 
P0-P2 days old C57BL/6 mice were plated, activated and incubated with fluorescent beads 
essentially as previously described (Al-Ali et al., 2017; Yli-Karjanmaa et al., 2019). As a measure of 
phagocytic activity, the number of engulfed beads/cell and cell morphology measured as cell area, 
membrane irregulatity and perimeter length were estimated by the automated counting software 
Puntomorph (https://github.com/HA-Lab/PuntoMorph) (Al-Ali et al., 2017). In order to ensure correct 
data processing, data were automatically transformed into excel data using an in-house made 
python program PuntoCalc.   
For purification of primary microglia, brains were collected in ice-cold Hanks’ Balanced Salt 
Solution (HBSS) without Ca2+ and Mg2+ (Thermo Fisher Scientific), cortices dissected and processed 
using Neural Tissue Dissociation Kit (P) (Miltenyi Biotech, Lund, Sweden) according to the 
manufacturer’s protocol. Next, microglia were purified by MACS sorting using magnetic CD11b+ 
beads on LS columns (Miltenyi Biotech) and cultured as 80,000-100,000 cells/well in 20% pre-
warmed foetal bovine serum (FBS)-DMEM complete medium (76% Dulbecco's Modified Eagle 
Medium (DMEM) + 20% heat inactivated FBS), 1% non-essential amino acids, 1% penicillin 
streptomycin, 1% GlutaMax and 1% pyruvate (all from Thermo Fisher Scientific)) on poly-L-Lysine-
coated plates in a humified CO2 incubator at 37 C. After 2-3 days, half of the media was changed 
to culture medium B (86% DMEM, 10% FBS, 1% MEM, 1% penicillin streptomycin, 1% 
GlutamaxTM, 1% pyruvate). Four days after the media change microglia were activated by adding 
100 ng/mL lipopolysaccharide (LPS) (Invitrogen, Thermo Fisher Scientific) and treated with either 
100 or 200 ng/mL XPro1595, or 100 or 200 ng/mL etanercept. Non-stimulated cells and cells 
stimulated with LPS were kept as controls. Microglia were then incubated at 37 C for 24 hours. °
Next day, FluoSpheresTM Carboxylate-Modified Microspheres (1.0 mm, 505/515, yellowgreen 
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fluorescent) (Thermo Fisher Scientific) were added onto the cultured cells. After 2 h, phagocytosis 
was terminated by adding ice-cold DMEM for 2-5 minutes. Cells were fixed with 4% PFA, blocked 
in 5% normal goat serum in TBS and incubated overnight in anti-Iba1 antibody (1:500, Table 2). 
The next day, cells were stained using alexa 594-conjugated anti-rabbit antibody (1:750, Molecular 
Probes) and 4’,6-diamidino-2-phenylindol (DAPI) (Thermo Fisher Scientific) and mounted using 
ProLong Diamond. In total, 12-15 pictures were randomly taken from each coverslip using a 20x 
magnification with an Olympus FluoView 1000 confocal microscope to ensure that it was possible 
to analyze at least 9 pictures per coverslip. Two independent experiments were performed.
2.15 Statistics
Statistical comparisons used two-tailed Student’s unpaired t-test for RT-qPCR, Western blot, 
monoamines, number of proliferating cells and neurons, the morphological analysis of E13.5 and 
P7, albumin, GLUT1 and claudin-5 expression, body weight, Y maze test, and elevated plus maze 
test. Comparisons between the number of microglia in E13.5, P7, adult WT and TNF-/- mice used 
one-tailed Student’s t-test as we previously found TNF-/- mice to have significantly fewer microglia 
than WT (Lambertsen et al., 2009). Comparisons between the mice treated with saline, XPro1595, 
or etanercept used i) one-way ANOVA followed by Tukey’s multiple comparisons test for Western 
blot, multiplex ELISA, proliferating cells, number of microglia, and Y maze test, ii) Repeated 
measures two-way ANOVA followed by Tukey’s post hoc test for body weight, and iii) Student’s 
paired t-test to compare performance in the open field test at one and two months after 
treatment. Phagocytosis assay was analysed using one-way ANOVA followed by Tukey’s post hoc 
test. Barnes maze learning curves from day 1 to day 4 were analyzed by repeated measures two-
way ANOVA followed by Tukey’s post hoc test. Comparisons of the average latency time in Barnes 
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maze between WT and TNF-/- mice used Student’s unpaired t-test, and comparisons between 
saline-, XPro1595-, or etanercept-treated mice by one-way ANOVA followed by Tukey’s post hoc 
test. The spatial memory retention on day 5 of Barnes maze was tested by repeated measures 
two-way ANOVA followed by Sidak’s multiple comparison’s test. Data are presented as 
mean±SEM. Statistical significance was set at p≤0.05.
3. Results
3.1 TNF deficiency alters the expression of genes related to neurogenesis and WNT signaling
To study cellular changes resulting from developmental TNF deficiency, we assessed the gene 
expression profile in the whole brain by whole-transcript microarray analysis of 28,853 genes in 2-
months old TNF-/- versus WT mice. We found 66 differentially expressed genes to be either 
upregulated (Figure 1A, blue bars) or downregulated (Figure 1A, red bars) in TNF-/- compared to 
WT mice, which included genes related to proinflammatory mechanisms, neurotransmission, lipid 
metabolism, and WNT signaling. By KEGG pathway analysis we identified the WNT and nuclear 
factor-kappa B (NF-B) signaling pathways, as well as neurogenesis and monoamine pathways 
related genes as the most affected (Figure 1B). Select differentially expressed genes (Figure 1A, 
bars indicated by light blue and light red colors) found through gene chip analysis were verified by 
RT-qPCR (Figure 1C-G). Comt1, Alox-8, and Fos were significantly lower in adult TNF-/- mice (Figure 
1C-F). On the microarray, Tnf was significantly upregulated, evidenced by the “Tnf see” primers 
(Supplementary table 1). However, as this is a non-functional Tnf mRNA, we also measured 
expression of functional Tnf mRNA using the “Tnf no-see” primers. Expression of intact Tnf was 
disrupted in TNF-/- mice, as expected (Figure 1G). Expression of Tnfrsf1a was comparable between 
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groups (Figure 1H), and Tnfrsf1b was downregulated in TNF-/- mice (Figure 1I). Expression of IL-1 
often correlates with TNF expression (Dinarello et al., 1986; Philip and Epstein, 1986), and we 
found that Il1a was upregulated in TNF-/- mice (Figure 1J), whereas Il1b and Il1rn were comparable 
between groups (Figure 1K,L). Finally, we also checked a number of genes involved in serotonergic 
and dopaminergic signaling, however, we saw no significant differences in expression of Scl6a4, 
Htr2a, Itgam, Nnt, Itpka, Tacr3, Snca, Asic1, and Park2 mRNAs (Supplementary table 1).
Genes related to neurogenesis were also differentially expressed in TNF-/- mice (Figure 1A-B). 
Gene chip analysis showed Cthrc1 and Fzd6 expression to be significantly lower in TNF-/- than WT 
mice (Figure 1A). Western blotting verified that protein expression of CTHRC1 (Figure 1M) and 
FZD6 (Figure 1N) was lower in TNF-/- mice compared to WT mice. In contrast, two months of 
XPro1595 treatment led to upregulation of CTHRC1 expression compared to saline and etanercept 
treatment (Figure 1O). Pharmacological TNF inhibition did not affect expression of FZD6 (Figure 
1P). 
3.2 TNF deficiency decreases cell proliferation
Due to the role of WNT signaling in cell proliferation, the observed altered RNA levels of genes in 
the WNT signaling pathway (Figure 1A,B), and changes in levels of WNT-signaling-related proteins, 
CTHRC1 and FZD6 (Figure 1M-N), we further investigated whether TNF deficiency might impact 
the number of proliferating cells in the developing brain. We analyzed the density of PH3+ 
proliferating cells in the developing neocortex of E13.5 mice (Figure 2A-B) and the density and 
number of Ki67+ proliferating cells in P7 mice (Figure 2C-D), comparing TNF-/- mice to WT 
littermates. The number of PH3+ cells/pixel in the VZ was lower at E13.5 in TNF-/- mice but was 
unchanged in the SVZ (Figure 2B). The density of Ki67+ cells in the SEZ (Figure 2C) and the total 
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number of Ki67+ cells in the dentate gyrus (Figure 2D) were significantly lower at P7 in TNF-/- 
compared with WT mice. 
To estimate potential changes in neurogenic zones, we also measured GE length and area in HE-
stained sections from E13.5 mice (Figure 2E-G) and estimated the volume of SEZ, lateral ventricles, 
and cortex in HE-stained sections from P7 mice (Figure 2H-J). We observed no significant 
differences in GE length and area between TNF-/- and WT mice at E13.5 (Figure 2F-G). In P7 mice, 
SEZ volume was significantly larger in TNF-/- than in WT (Figure 2H), whereas the volumes of the 
lateral ventricles (Figure 2I) and the neocortex (Figure 2J) were comparable. 
Due to the altered cell proliferation in the neurogenic zones of E13.5 and P7 mice, we investigated 
if long-term use of TNF inhibitors would cause similar changes in adult mice. First, we injected 
mice with BrdU (Figure 2K-L) prior to treatment with saline, XPro1595, or etanercept to test the 
effect of long-term TNF inhibition on the number of BrdU+ cells in the dentate gyrus. Second, to 
test the effect of treatment on spatial learning and memory, we injected EdU (Figure 2M-N) after 
7 weeks of saline, XPro1595, or etanercept administration, just prior to subjecting the mice to a 
spatial leaning and memory test and 1 week before euthanization. Etanercept treatment reduced 
the number of BrdU+ cells in the granular cell layer of dentate gyrus in adult mice compared to the 
saline-treated group, whereas XPro1595 had no effect (Figure 2L). There were no differences in 
the number of EdU+ cells between groups (Figure 2N). 
3.3 TNF deficiency decreases the number of cortical microglia during development and increases 
the number of neurons in adult mice
Since absence of TNF during development decreased the number of proliferating cells and altered 
the spatial organization of the neurogenic zones of the brain, we assessed whether this was 
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associated with changes in the number of neocortical neurons and microglia (Figure 3). We 
estimated cell density using densitometry or estimated the total number of cells using a 
stereological approach. The density of immature neocortical doublecortin (DCX)+ neurons in E13.5 
mice did not change between genotypes (Figure 3A-B). However, the total number of Iba1+ 
microglia and the number of ramified Iba1+ microglia in the cortex of E13.5 mice was significantly 
lower in TNF-/- than WT mice, just as the percentage of ramified Iba1+ microglia of all Iba1+ 
microglia was lower in TNF-/- mice compared to WT (Figure 3C-D). In the cortex at P7, the number 
of TB+ neurons were higher in TNF-/- mice compared WT (Figure 3E), whereas microglia were 
significantly fewer (Figure 3F). In adult TNF-/- mice, the number of TB+ neurons was significantly 
increased (Figure 3G) and the number of CD11b+ microglia decreased (Figure 3H), in line with our 
previous report (Lambertsen et al., 2009). Following long-term treatment (2 months) with TNF 
inhibitors, we found no differences in cortical microglia numbers, suggesting that long-term 
treatment with XPro1595 or etanercept does not affect microglial numbers in the healthy, adult 
C57BL/6 mouse brain (Figure 3I-J). 
3.4 TNF affects microglial phagocytosis
Since developmental TNF deficiency resulted in decreased number of neocortical microglia and an 
increased number of neurons, we next investigated whether deficiency in either solTNF and 
tmTNF or solTNF only affected microglial phagocytosis following LPS activation (Figure 4A). At day 
1 after LPS stimulation, we found that 100 and 200 ng/mL XPro1595 significantly increased the 
number of phagocytosed beads/cells compared to control, to LPS stimulation only, and to LPS + 
100 or 200 ng/mL etanercept (Figure 4B). In contrast, etanercept treatment completely blocked 
phagocytosis (Figure 4B). Cell area (Figure 4C), perimeter length (Figure 4D), and membrane 
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irregularity (Figure 4E) increased significantly following LPS and LPS + XPro1595 treatment, 
whereas etanercept completely blocked these changes in cell morphology (Figure 4C-E). This 
suggests that TNF is essential for microglial phagocytosis, and that ablating solTNF may even 
increase phagocytosis.
3.5 TNF deficiency or long-term inhibition of TNF has no effect on body weight 
At P7, body weights of WT mice (4.01 g  0.15 g, n=8) and TNF-/- mice (3.58 g  0.50 g, n=9) did not 
differ between genotypes (p=0.06, Student’s unpaired t-test), and growth rate of saline, XPro1595, 
or etanercept treated mice was comparable between treatment groups, although weights 
increased significantly over time (two-way ANOVA: time p<0.0001 F18,594=72.82; treatment p=0.15 
F2,33=2.00; interaction p=0.97 F3,594=0.60). This supports earlier findings that genetic ablation of 
solTNF has no effect on body weight (Madsen et al., 2016). 
3.6 TNF deficiency does not affect BBB permeability 
Interaction of TNF with cerebral endothelial cells can affect paracellular permeability of the BBB, 
including changes in tight junction protein expression (reviewed in (Pan and Kastin, 2007)). To 
assess the effect of TNF deficiency on BBB permeability, we evaluated albumin leakage into the 
CNS parenchyma (Figure 5A-B), the expression of the tight junction protein claudin-5 (Figure 5C-D) 
and the glucose transporter GLUT1 (Figure 5E-F). Expression of all of these molecules, quantified 
by measuring the relative staining intensity, was comparable between E13.5 WT and TNF-/- mice 
(Figure 5B,D,F), suggesting that TNF deficiency does not affect the BBB under non-inflammatory 
conditions. 
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3.7 Two months of TNF-inhibitor treatment has no effect on plasma cytokines 
To see whether long-term TNF inhibition altered circulating cytokine levels, we measured plasma 
expression levels of TNF, IL-1β, IL-6, IFNγ, CXCL1, IL-10, IL-12p70, IL-2, IL-4, and IL-5 two months 
after onset of saline, XPro1595, or etanercept treatment. XPro1595 for two months significantly 
upregulated TNF levels (Figure 6A), but we observed no effect of XPro1595 or etanercept on other 
plasma cytokines (Figure 6B-J). 
3.8 TNF deficiency alters monoamine levels and turnover rates 
Previous findings on the role of TNF in learning and memory (Golan et al., 2004a), the observed 
alterations in the monoamine pathways (Figure 1B), and the downregulation of Comt1 mRNA 
expression in the brain of TNF-/- mice (Figure 1C) prompted us to investigate possible changes in 
the levels of monoamines and their metabolites in various brain areas by HPLC (Table 3 and 
Supplemental Table 2). No differences in 5-HT levels were observed in any of the measured brain 
regions (Supplemental Table 2). However, developmental TNF deficiency increased 5-HT turnover 
in hippocampus, brainstem, and cerebellum, giving higher 5-HIAA levels in hippocampus and 
brainstem and a higher 5-HT turnover in cerebellum (based on an elevated 5-HIAA/5-HT ratio). 5-
HIAA was upregulated in the striatum of TNF-/- mice without a change in the turnover rate (Table 3 
and Supplemental Table 2). Dopamine levels were similar in WT and TNF-/- mice in all brain 
regions (Supplemental Table 2). The metabolite DOPAC was lower in the prefrontal cortex of TNF-
/- mice, and upregulated in the brain stem (Table 3). The DOPAC/DA turnover ratio was increased 
in hippocampus and brainstem. HVA was upregulated in the striatum of TNF-/- mice, and the 
HVA/DA turnover ratio was increased in striatum and occipital cortex of TNF-/- mice. NA levels did 
not differ between genotypes (Supplemental Table 2). Levels of DA, DOPAC and HVA are usually 
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very low in the cerebellum, often below detection limits, and were thus omitted from the 
statistical analysis. 
3.9 Non-selective TNF inhibition causes learning impairment
Both developmental TNF deficiency and long-term TNF inhibition altered the number of 
proliferating cells in the adult mouse brain. As neurogenesis in the dentate gyrus of the 
hippocampus has been linked to learning and memory functions, we performed a spatial learning 
and memory retention test (Barnes maze) in adult TNF-/- mice versus WT littermates (Figure 7A-C) 
and in adult C57BL/6 mice treated long-term with saline, XPro1595, or etanercept (Figure 7D-F). 
When comparing naïve WT and TNF-/- mice, WT mice learned the task over time, as shown by the 
reduced latency (time) to find the goal box at day 3 and day 4 as compared to day 1 (Figure 7A). 
TNF-/- mice found the goal box rapidly during all four days of the learning phase (Figure 7A). 
Already on day 1, TNF-/- quickly found the hidden goal box, at which time point the TNF-/- displayed 
significantly decreased latency time to find the hidden goal box compared to WT mice (Figure 7B).  
On day 5 the goal box was removed.  During the first four trials on day 5, the visual cues were 
placed similarly as on days 1 to 4. On the fifth trial, the cues were placed randomly to test memory 
retention. The mice exhibited comparable memory retention patterns (Figure 7C), spending equal 
time in the quadrant zones (p=0.19). 
We then tested adult C57BL/6 mice after long-term exposure to TNF inhibitors. Both saline- and 
XPro1595-treated mice showed improved learning as they were significantly faster in finding the 
hidden goal box on day 2, 3, and 4 compared to day 1 (Figure 7D). XPro1595-treated mice showed 
improved learning over time (Figure 7D). This was not observed in the etanercept-treated group, 
indicating impaired learning (Figure 7D). The etanercept-treated mice also took significantly more 
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time to find the goal box on days 3 and 4 compared to the saline- and XPro1595-treated mice 
(Figure 7E). The treatment groups spent similar amounts of time searching for the goal box on day 
5, excluding trial 4 when XPro1595-treated mice spent more time than the others in target zone, 
and etanercept-treated mice spent more time in opposite zone than XPro1595-treated mice 
(Figure 7F). Etanercept-treated mice thus displayed impaired learning curve on the Barnes maze, 
but memory retention on day 5 was comparable in the three groups.
3.10 TNF deficiency has no effect on activity, anxiety-related behavior, or exploratory behavior
Effects of developmental TNF deficiency on activity, anxiety-related behavior, and exploratory 
behavior in adult mice were assessed by testing WT and TNF-/- mice on the Y maze and elevated 
plus maze. TNF deficiency had no effect on locomotor activity when measured as the travelled 
distance in the elevated plus maze (Figure 8A). There were no differences between the genotypes 
in the time the mice spent in the open or closed arm (Figure 8B), suggesting that developmental 
TNF deficiency has no effect on anxiety-related behavior of the mice, nor were there differences in 
spontaneous alternation behavior between WT and TNF-/- mice (Figure 8C), suggesting that the 
working memory of the mice was intact. 
To test whether the impaired learning of etanercept-treated mice (Figure 7D) was due to a lack of 
natural anxiety-related behavior, we evaluated characteristics associated with anxiety-related 
behavior in the open field test after treatment with saline, XPro1595, or etanercept. First, we 
measured the total travel distance of the animals during the test to exclude the possibility that the 
treatment affected their locomotor activity. We found no differences in the total distance 
travelled between mice treated for one and two months in any of the groups (Figure 8D). In the 
open field test, saline- and XPro1595-treated animals had significantly fewer entries into the 
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center zone after two months of treatment than after one month of treatment (Figure 8E). The 
center-perimeter ratio decreased significantly in all three groups between one and two months of 
treatment (Figure 8F). The number of dropped fecal boli was comparable between the treatment 
groups after one and two months of treatment (Figure 8G). The time spent in the wall zone 
increased in all treatment groups, and the time spent in the center zone decreased in all treatment 
groups between one and two months of treatment (Figure 8H), suggesting that etanercept-
treated mice were not anxious. Exploratory behavior measured as rearing was comparable in all 
groups (Figure 8I-J). Spontaneous alternation behaviors in the Y maze were comparable between 
saline, XPro1595, and etanercept treated mice (Figure 8K). In conclusion, neither developmental 
TNF deficiency nor treatment with XPro1595 or etanercept had any significant effect on anxiety or 
exploratory behavior in adult mice. 
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4. Discussion
In this study, we found that TNF deficiency altered the expression of genes and proteins related to 
neurogenesis and WNT signaling, which impacted the organization of the neurogenic zones and 
altered the composition of microglia and neurons in the neocortex of the brain. We also found 
that long-term inhibition of TNF with the non-selective inhibitor etanercept reduced the number 
of BrdU+ cells in the granule cell layer of the the dentate gyrus and impaired learning and memory.
TNF has been shown to be important for synaptic transmission and homeostatic synaptic scaling 
(Beattie et al., 2002; Kaneko et al., 2008; Stellwagen and Malenka, 2006) and TNF expression 
regulates WNT signaling (Hiyama et al., 2013; Zhao et al., 2015). In the present study, we found 
that TNF deficiency regulates the expression of genes and proteins related to WNT signaling, as we 
observed lower levels of FZD6 and CTHRC1 in TNF-/- mice compared to WT littermates. Given the 
importance of these proteins in stabilizing the WNT receptor complex, changes potentially could 
lead to alterations in the number of proliferating cells. Thus, we investigated the effect of TNF on 
cell proliferation. We found that TNF deficiency decreased cell proliferation in VZ, SVZ, SEZ, and 
dentate gyrus during development. These findings are in agreement with studies demonstrating 
that TNF promotes apoptotic cell death in hippocampal cultures and in newborn hippocampal 
progenitor cells (Cacci et al., 2005; Zhao et al., 2001). TNF has also been shown to suppress neural 
progenitor cell proliferation but increases the migration in vitro (Ben-Hur et al., 2003); these 
results are at odds, however, with previous studies showing that maternal immune activation can 
also result in reduced proliferation in the embryonic VZ (Stolp et al., 2011) and that adult neural 
stem cells display impaired proliferation when exposed to TNF (Wong et al., 2004). It is likely that 
the mechanisms of these proliferation changes are different, as the concentration of TNF was 
found to be the regulating factor in cell proliferation, with a low TNF dose increasing cell 
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proliferation and a high dose causing cell death (Bernardino et al., 2008). In our study, we found 
TNF-/- mice to have reduced TNFR2 mRNA expression. As earlier studies found that TNFR2 
deficiency reduced neurogenesis (Chen and Palmer, 2013), the suppressive effect of TNF on cell 
proliferation could potentially be mediated through TNFR2, as suppression of cell proliferation 
promotes the differentiation of neural progenitor cells into neurons. 
We found that TNF not only regulated cell proliferation in the neurogenic niche but also altered 
microglial and neuronal numbers in the neocortex. TNF deficiency reduced the number of 
microglia and increased the number of TB+ neurons, data which are in line with previous studies by 
our lab demonstrating reduced numbers of CD45dimCD11b+ microglia in adult TNF-/- mice 
(Lambertsen et al., 2009). Microglia are known to regulate the number of newborn neurons in the 
dentate gyrus by phagocytosis (Sierra et al., 2010). In TNF-/- mice, the increased number of 
neurons could be a result of impaired microglial phagocytosis. This is supported by our findings 
showing that etanercept completely blocks phagocytosis in primary microglial cultures stimulated 
with LPS, compared to XPro1595, which results in increased phagocytosis. We have also recently 
shown that compared to WT microglia, microglia expressing only tmTNF display decreased 
expression of Methyl-CpG-binding protein 2 (MECP2)(Yli-Karjanmaa et al., 2019), a protein 
involved in microglia responsiveness to environmental stimuli to promote homeostatis. Therefore, 
given the findings that MECP2-deficient mice display decreased number of microglia compared to 
WT mice (Cronk et al., 2015), it is possible that solTNF, rather than tmTNF, plays a role in 
microgliogenisis during development. 
The increased number of neurons in TNF-/- mice could also be a result of the abnormally low 
number of microglia. Newborn neurons typically undergo extensive apoptosis during embryonic 
development where up to 70% of cells die before integrating into the existing neuronal circuit 
35
(Thomaidou et al., 1997). Microglia that phagocytose newborn neurons are not activated but 
express a ramified morphology in their unchallenged state (Sierra et al., 2010). We found a lower 
total number of microglia but also a lower percentage of ramified cells at E13.5, implying that 
fewer microglia were in a phagocytic state in TNF-/- mice. In support of this, we show 
downregulated mRNA expression of Lpl in adult TNF-/- mice. In CNS, Lpl is mainly expressed in the 
hippocampus, and the highest expression of Lpl mRNA is detected in microglia (Zhang et al., 2014; 
Zhang et al., 2016). Earlier studies show LPL to be an important regulator of phagocytosis and 
innate immunity (Gao et al., 2017) and th supports cognitive functions, where neuronal Lpl knock-
out mice showed increased anxiety and impaired learning and memory (Yu et al., 2015).
Microglia colonize the brain in waves. The first wave from the yolk sac to the embryo arrives 
before E8 and infiltrates the brain at E9, where the cells can be detected at E9.5 (Ginhoux et al., 
2010). By E20, the distribution of microglia in the brain is nearly homogenous (Squarzoni et al., 
2014). Angiogenesis occurs at the same time, and the BBB is formed with the endothelial cell layer 
developing on E10-E11. WNT signaling can regulate angiogenesis in the developing brain 
(Daneman et al., 2009), and the barrier can be vulnerable to environmental disturbances, 
depending on the local inflammatory environment and the stage of brain/vascular maturation 
(Blanchette and Daneman, 2015; Stolp et al., 2005; Stolp et al., 2009). Passive BBB permeability is 
controlled by the tight junctions connecting the endothelial cells, and any disturbance in 
permeability could alter microglial infiltration. To rule out developmental defects in the BBB that 
could account for the decrease in microglial number in TNF-/- mice, we investigated the expression 
of a major tight junction protein, claudin-5 (Morita et al., 1999a; Morita et al., 1999b), which is 
expressed from E12 (Daneman et al., 2010). TNF secreted in an inflammatory environment 
decreases the expression of claudin-5 both in vivo and in vitro, thereby increasing BBB 
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permeability (Aveleira et al., 2010; Dickstein et al., 2000; Forster et al., 2008; Nishioku et al., 2010). 
However, claudin-5 expression was comparable between WT and TNF-/- mice and further 
investigation of albumin leakage through capillaries and of GLUT1 expression revealed no 
differences between the mice. This suggests that TNF deficiency had no impact on angiogenesis or 
BBB permeability, which could account for the reduced microglial numbers. 
In the microarray analysis and supported by RT-qPCR, we found that Comt1 gene expression was 
decreased in TNF-/- mice. Comt1 encodes COMT, known to convert DA to 3-methoxytyramine or 
DOPAC to HVA. We did not assess 3-methoxytyramine, however, we measured levels of DA, 
DOPAC, and HVA. Instead of finding higher DOPAC and lower HVA levels, which is expected if 
COMT activity is reduced, we observed significantly increased HVA levels and HVA/DA ratio in 
striatum and a tendency of such increases in other brain regions. Since DOPAC/DA ratios were not 
different in TNF-/- mice, we cannot conclude that DA turnover was altered. However, we observed 
increased 5-HT turnover (increased 5-HIAA/5-HT ratios) in hippocampus, brain stem, and 
cerebellum. This supports previous findings showing increased 5-HT and 5-HIAA in hippocampus, 
thalamus, medulla oblongata/pons, and cerebellum of TNF-/- mice (Yamada et al., 2000). The 
observed changes in monoamine metabolites in this study cannot be linked to possible alterations 
in behavior as we observed there were no behavioral changes in TNF-/- mice compared to WT 
littermates. Alterations in serotonergic signaling have been linked to increased or decreased 
neurogenesis in the hippocampus, probably mediated by neurotrophins and cytokines (Haase and 
Brown, 2015). Long-term treatment with anti-depressive drugs, including selective serotonin 
reuptake inhibitors, increases extracellular levels of 5-HT in hippocampus (Cremers et al., 2007), 
reduces 5-HT turnover as assessed by reductions in 5-HIAA/5-HT ratios in brain tissue (Conti et al., 
2014), and increases neurogenesis in experimental animals (Malberg et al., 2000). We observed 
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significant increases in 5-HT turnover in hippocampus of adult TNF-/- mice, which may be related to 
the observed reductions in proliferating cells.
Given the importance of TNF in the spatial organization of neurogenic zones and the effect of TNF 
deficiency on microglial and neuronal numbers, we next investigated the effect of long-term TNF 
inhibitor treatment on the WNT signaling proteins CTHRC1 and FZD6, cell proliferation and 
learning and memory in healthy adult mice. We found that mice treated with XPro1595 for two 
months had significantly higher expression of CTHRC1 compared to saline-treated mice, whereas 
treatment with etanercept had no effect. We saw the same tendency for FZD6. This suggests that 
tmTNF, but not solTNF, is needed for functional WNT signaling. We therefore also estimated the 
total number of BrdU+ cells in the dentate gyrus and the number of neocortical microglia after two 
months of TNF-inhibitor treatment. We found that long-term inhibition of TNF had no effect on 
neocortical microglial numbers, however, etanercept significantly reduced the number of BrdU+ 
cells in the granule cell layer of dentate gyrus. This correlated with etanercept-treated mice 
displaying impaired spatial learning on the Barnes maze test. As hippocampus-dependent learning 
can induce neurogenesis (Gould et al., 1999), we also estimated the total number of EdU+ cells in 
the dentate gyrus following Barnes maze induced learning and memory. We found, however, that 
neither XPro1595 nor etanercept had any effect the number of EdU+ proliferative cells in the 
dentate gyrus after the Barnes maze test. These findings suggest, that though non-selective TNF 
inhibition affects learning induced memory it does not affect learning-induced neurogenesis. One 
week of learning may, however, have been too short to detect differences in proliferative cells.
It should be mentioned that the present studies using TNF inhibitors were done in healthy animals 
under normal brain homeostasis where TNF is constitutively released at physiological relevant 
levels to keep proper synaptic plasticity. In contrast, when central TNF levels dramatically increase, 
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the synaptic action of TNF remarkably interferes with brain circuits of learning and congnition and 
contributes to excitotoxicity and neurodegeneration. Multiple sclerosis (MS) and Alzheimer’s 
disease (AD) are prototypical neuro-inflammatory and -degenerative diseases in which 
inflammation triggers excitotoxic mechanisms contributing to neurodegeneration and in which 
TNF is chronically increased (Rossi et al., 2014; Tarkowski et al., 2003). In this scenario, TNF starts 
to exert noxious effects on synaptic transmission and to account for effects associated with 
memory and learning deficits (reviewed in (Chang et al., 2017)). In experimental animal models of 
MS and AD, it has been shown that peripheral inhibition of solTNF using XPro1595 attenuates 
disease, cognitive and long-term potentiation deficits (Brambilla et al., 2011; MacPherson et al., 
2017; Taoufik et al., 2011). 
Non-selective TNF inhibitors such as etanercept are currently used to treat patients suffering from 
peripheral chronic inflammatory diseases, such as rheumatoid arthritis (RA) and inflammatory 
bowel disease (IBD), where these drugs successfully reduce the excessive detrimental TNF levels 
associated with these diseases. In RA and sarcoidosis patients, treated with non-selective TNF 
inhibitors, cognition significantly improved (Chen et al., 2010; Elfferich et al., 2010). Furthermore, 
in IBD patients, the incidence of Parkinson’s disease in patients treated with non-selective TNF 
inhibitors significantly decreased (Peter et al., 2018) and in RA patients, the incidence of AD 
decreased (Chou et al., 2016). This clearly indicates a beneficial effect of anti-TNF treatment on 
brain function in patients suffering from chronic inflammatory diseases. It should be mentioned, 
however that treatment with non-selective TNF inhibitors in these patients can be associated with 
neurological side effects such as demyelinating diseases (reviewed in (Scheinfeld, 2004)). Whether 
XPro1595 has a potential advantage over etanercept in these patients remains to be clarified. As 
we in the present study did not investigate the possible effects of TNF inhibition on synaptic 
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pruning and other memory formation processes, it is unclear how XPro1595 and etanercept would 
alter brain wiring processes during adolescence. Also, whether XPro1595 has a potential 
advantage over etanercept on the spatial organization of the neurogenic zones and on microglial 
and neuronal numbers during development and in adolescent under chronic neuroinflammatory 
conditions remains to be clarified.
In conclusion, we show that developmental TNF deficiency decreases the number of neocortical 
microglia and increases the number of neocortical neurons. We also report that long-term use of 
nonselective TNF inhibitors in healthy, adult mice can alter neurogenic zones and impair learning 
and memory. 
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Figure legends
Figure 1. TNF deficiency alters expression of genes and proteins in WNT signaling pathway. (A) 
RNA fold change of the differently expressed genes in TNF-/- (n = 4) versus WT (n = 4) brains. Blue 
is upregulated and red is downregulated in TNF-/- mice compared with WT mice. Bars in lighter 
colors represents genes verified using RT-qPCR. (B) Pathway analysis of differentially regulated 
genes. (C-F) Comt1 (C), Alox-8 (D), Lpl (E), and Fos (F) mRNA downregulation in TNF-/- mice (4-
10/group). (G-L) Gene expression of Tnf (G), Tnfrsf1a (H), Tnfrsf1b (I), Il1a (J), Il1b (K), Il1rn (L) (4-
10 mice/group). (M-N) CTHRC1 (M) and FZD6 (N) protein levels were reduced in TNF-/- mice 
compared to WT mice (12-13/group). (O) CTHRC1 protein levels were upregulated in XPro1595-
treated mice compared to saline- and etanercept-treated mice (7/group). (P) FZD6 protein levels 
were comparable in saline-, XPro1595-, and etanercept-treated mice (5/group). *p0.05, 
**p<0.01, ***p<0.001, Student’s t-test or one-way ANOVA with Tuckey’s post hoc.
Figure 2. TNF deficiency decreases neurogenesis. (A) PH3+ cells in SVZ and VZ in E13.5 WT and 
TNF-/- mice. Scalebar = 200µm. (B) Estimation of PH3+ cells/pixel in SVZ and VZ in E13.5 mice (8-
12/group). (C) SEZ Ki67 cell density and (D) number of Ki67+ cells in the dentate gyrus (DG) of P7 
WT and TNF-/- mice (4-6/group). (E) HE-stained E13.5 brains used for GE length and area 
estimations. Scalebar = 200µm. (F) GE length in E13.5 mice (3-10/group). (G) GE area in E13.5 mice 
(3-10/group). (H) SEZ volume in P7 mice (6-7/group). (I) Volume of lateral ventricles in P7 mice (6-
7/group). (J) Cortical volume in P7 mice (6-7/group). (K) BrdU+ cells in granular cell layer (GC) of 
dentate gyrus in saline-, XPro1595-, and etanercept-treated mice. Scalebars = 100µm and 10µm 
(high magnification). (L) Number of BrdU+ cells in granular cell layer (GCL) of dentate gyrus in 
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saline-, XPro1595-, and etanercept-treated mice (5-8/group). (M) EdU+ cells in dentate gyrus of 
saline-, XPro1595- and etanercept-treated mice. Scalebars = 100µm and 10µm (high 
magnification). (N) Number of EdU+ cells in granular cell layer (GCL) of dentate gyrus in saline-, 
XPro1595-, and etanercept-treated mice (6-7/group). *p0.05, **p<0.01, Student’s t-test or one-
way ANOVA with Tuckey’s post hoc.
Figure 3. TNF deficiency alters the cortical cell composition. (A) DCX+ staining in E13.5 mice, 
scalebar = 100µm. (B) The relative intensity of DCX+ cells in developing neocortex was comparable 
in E13.5 WT and TNF-/- mice (3/group). (C) Iba1+ cells in the developing neocortex of E13.5 mice, 
scalebar = 100µm and 20µm (high magnification). (D) Number and percentage of Iba1+ cells in 
cortex of WT and TNF-/-  E13.5 (3-10/group). (E) Number of TB+ neurons in neocortex of WT and 
TNF-/- P7 mice (5/group). (F) Number of Iba1+ microglia in cortex of WT and TNF-/- P7 mice 
(5/group). (G) Number of TB+ neurons in cortex of adult WT and TNF-/- mice (6/group). (H) Number 
of CD11b+ cells in neocortex of adult WT and TNF-/- mice (6/group). (I) Iba1+ microglia in mice 
treated with saline, Xpro1595, or etanercept, scalebar = 20 µm. (J) Number of Iba1+ microglia in 
cortex of adult saline-, XPro1595-, and etanercept-treated mice (7-8/group). *p0.05, **p<0.01, 
Student’s t-test or one-way ANOVA with Tuckey’s post hoc.
Figure 4. TNF depletion impairs phagocytosis. (A) Primary cultures stained for Iba1 (red) and DAPI 
(blue) demonstrating phagocytosis of FluoSpheres Carboxylate-Modified Microspheres (green). 
Scale bar = 80 m. (B) Engulfed beads/cell in Ctl microglia (n=54) and in LPS (n=53), LPS + 100 
ng/mL (n=32) or 200 ng/mL (n=35) XPro1595, and LPS + 100 ng/mL (n=9) or 200 ng/mL (n=20) 
etanercept treated microglia. (C-E) Morphological features of microglia before and after LPS 
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stimulation with and without XPo1595 or etanercept. (C) Cell area. (D) Perimeter length. (E) 
Membrane irregularity. One-way ANOVA with Tukey’s post hoc test. ***p<0.001, **p<0.01. 
Asterisks (*) indicate significant differences compared to Ctl, hashtags (#) indicates significant 
differences compared to XPro1595 treatment, and the double-s (§) indicates significant 
differences compared to LPS treatment. Ctl, control; Etan, etanercept; LPS, lipopolysaccharide; 
XPro, XPro1595. 
Figure 5. TNF deficiency does not compromise BBB permeability. (A) Albumin staining in E13.5 
WT and TNF-/- mice. (B) Relative intensity of albumin in the developing neocortex of E13.5 WT and 
TNF-/- mice (7-11/group). (C) Claudin-5 staining in E13.5 WT and TNF-/- mice. (D) Relative intensity 
of claudin-5 in the developing neocortex of E13.5 WT and TNF-/- mice (3-13/group). (E) GLUT1 
staining in E13.5 WT and TNF-/- mice. (F) Relative intensity of GLUT1 in the developing neocortex of 
E13.5 WT and TNF-/- mice (3-7/group). Scalebars = 100µm and 10µm (insert). Student’s t-test.
Figure 6. Plasma cytokine profile after two months of treatment with saline, XPro1595, or 
etanercept. Plasma levels of TNF (A), IL-1β (B), IL-6 (C), interferon-gamma (IFNγ) (D), CXCL1 (E), IL-
10 (F), IL-12p70 (G), IL-1 (H), IL-4 (I), and IL-5 (J) (7-8 mice/group), *p≤0.05, one-way ANOVA with 
Tukey’s post hoc test.
Figure 7. Barnes maze spatial learning and memory retention test. (A) Learning curve of WT and 
TNF-/- mice presented as latency (time) to find the goal box in each trial (7-8 mice/group), ** 
p<0.01, ***p<0.001 compared to average latency on  day 1, two-way ANOVA with Tukey’s post 
hoc test. (B) Average latency to find a goal box on days 1 to 4. **p<0.01, ***p<0.001 compared to 
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average latency on day 1 within the genotype; two-way ANOVA with Tukey’s post hoc test;  
#p≤0.05 compared to average latency between genotypes; Student’s unpaired t-test. (C) Time 
spent on different zones of the Barnes maze on day 5. (D) Learning curve of saline-, XPro1595-, 
and etanercept-treated mice (8/group), **p<0.01, ***p<0.001, ****p<0.0001 compared to 
average latency on day 1; two-way ANOVA with Tukey’s post hoc test. (E) Average latency to find a 
goal box, **p<0.01, ***p<0.001, ****p<0.0001 compared to average latency on day 1 within the 
genotype; two-way ANOVA with Tukey’s post hoc test; #p≤0.05, # p<0.01 compared to average 
latency between genotypes, one-way ANOVA with Tukey’s post hoc test.  (F) Time spent in 
different zones on day 5, *p≤0.05 for XPro1595-treated mice compared to saline- and etanercept-
treated mice in target zone on trial 4; ##p<0.01 for etanercept-treated mice compared to 
XPro1595-treated mice in opposite zone on trial 4; two-way ANOVA with Sidak’s multiple 
comparisons test.
Figure 8. TNF deficiency has no effect on anxiety or exploratory behavior in mice. (A) Locomotor 
activity measured as distance travelled in elevated plus maze for WT and TNF-/- mice (7-9/group). 
(B) Anxiety-related behavior of WT and TNF-/- mice measured as the open/closed arm ratio. (C) 
Working memory and exploratory behavior of WT and TNF-/- mice measured as spontaneous 
alternation between the arms in the Y maze (12-16/group). (D-J) Locomotor activity and anxiety-
related behavior of saline-, XPro1595-, and etanercept-treated mice measured as the travelled 
distance (D), entries into the center zone (E), center/perimeter ratio (F), number of dropped fecal 
boli (G), percentage time in wall and center zones (H), wall rearing (I), and center rearing (J) in the 
open field test (8/group). (K) Working memory and exploratory behavior measured as 
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spontaneous alternation between the arms in the Y maze (8/group). *p≤0.05, **p<0.01, 
***p<0.001, Student’s paired t-test.
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R: 5’ TCACCCCGAAGTTCAGTAGACAGA 3’ 24 63 50.00
Tnf "no see" F: 5’ TCTTCTCATTCCTGCTTGTGGC 3' 100 22 61 50.00 Lambertsen et al., 2009
R: 5’ AGGCCATTTGGGAACTTCTCATC3' 23 61 47.83
Tnfrsf1 F: 5’ GCCCGAAGTCTACTCCATCATTTG 3' 91 24 61 50.00 Lambertsen et al., 2007
R: 5’ GGCTGGGGAGGGGGCTGGAGTTAG 3' 24 70 70.83
Tnfrsf2 F: 5’ GCCCAGCCAAACTCCAAGCATC 3’ 133* 21 64 57.14 Lambertsen et al., 2007
R: 5’ TCCTAACATCAGCAGACCCAGTG 3’ 23 62 52.17
Il1b F: 5’ TGTAATGAAAGACGGCACAC 3’ 68* 20 56 45.00 Clausen et al., 2016
R: 5’ TCTTCTTTGGGTATTGCTTGG 3’ 21 56 42.86
Il1a F: 5' GTCGGCAAAGAAATCAAGATG 3' 78 21 56 42.86 Clausen et al., 2016
R: 5'GTCTTCGTTTTCACTGTAACAG 3' 22 56 40.91
I l 1 r n F : 5' AACCAGCT ATTGCTGGGTACTTA 3' 95* 23 60 43.48 Clausen et al., 2016
R: 5' GCCCAAGAACACACTATGAAGGTC 3' 24 62 50.00
Scl6a4 (5-HTT) F: 5' CTCCTACTATAACACCATCA 3' 182 20 51 40.00
R: 5' GCAAGTAAAACTCCTCAG 3' 18 50 44.44
Probe R: 5' CGCTCTACTACCTCATCTCCTCCT 3' 24 59 54.00
Htr2a F: 5' CAGCAGAAACAGAAATCAA 3' 187 19 51 36.84
R: 5' GTGACTTTAAGCAGAAAGAA 3' 20 51 35.00
Probe F: 5' ACAGCAGCCGAGGAACTTACA 3' 21 54 52.00
Itgam (CD11b) F: 5’ CGGAAAGTAGTGAGAGAACTGTTTC 3' 114 25 60 44.00 Lambertsen et al., 2009
R: 5’ CTTATAATCCAAGGGATCACCGAATTT 3' 27 60 37.04
Nnt F: 5' GTCCAGTAATCCACCTTCA 3' 85 19 54 47.37
R: 5' CACCACCGTCTTCAGTAG 3' 18 54 55.56
Itpka F: 5' GTGCTGAGGAGGTATCTG 3' 76 18 60 55.60
R: 5' CGTGCCGTCTAAAGAATC 3' 19 61 47.40
Tacr3 F: 5' GCCGTACCCTTTGCTATGT 3' 330* 19 58 52.63
R: 5' GGTAGACCTGCTGGATGTATTT 3' 22 58 45.45
Snca F: 5' TGGAGGGAGCTGGGAATATAG 3' 206* 21 58 52.38
R: 5' CTTAGGAGATTGGGTGCAATGA 3' 22 58 45.45
Park2 F: 5' GTCCAGTTAAACCCACCTACAA 3' 240* 22 58 45.45
R: 5' TTGGGTGTGCTCCACATTTA 3' 20 57 45.00
Asic F: 5' CTAGTGGAGAAAGACCAGGAATAC 3' 276 24 58 45.83
R: 5' CCCGATGAACAATCCCATCT 3' 20 57 50.00
Hprt1 F’: 5’AAGCAGTACAGCCCCAAAATG 3’ 93* 21 59 47.62 Meldgaard et al., 2006
R’:5’AAATCCAACAAAGTCTGGCCTGTA 3’ 24 61 41.67
F, forward; R, reverse
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Red demarcates exon-exon junction
*, one or more exon-exon junction(s) within the pcr product
Table 2. Antibodies applied for immunohistochemical staining.
Protein of interest Antibody Isotype Species of origin Cat. #
IMMUNOHISTOCHEMISTRY
Primary antibodies:
E13.5:
Phosphohistone H3 (Ser10)
Ionized calcium binding adaptor molecule 1
Doublecortin
Claudin-5
Glucose transporter-1
Albumin
P7:
Ionized calcium binding adaptor molecule 1
Ki-67 
Adult:
Integrin alpha M chain (CD11b)
Ionized calcium binding adaptor molecule 1
5-Bromodeoxyuridine 
Isotype/serum controls:
PH3 (1:500)
Iba1 (1:500)
DCX (1:500)
CLDN5 (1:500)
GLUT-1 (1:500)
Albumin (1:500)
Iba1 (1:500)
Ki-67 (clone SP6) (1:500)
CD11b (clone 5C6) (1:600)
Iba1 (1:350)
BrdU (clone BU1/75 
(ICR1)) 1:600 
Un-conjugated
Un-conjugated
Un-conjugated
Ig fraction
Ig fraction
Ig fraction
Ig fraction
Ig fraction
Ig fraction
Ig fraction
IgG
IgG2b
Ig fraction
IgG2a
IgG2b
Ig fraction
IgG2a
Rabbit
Goat
Rabbit
Rabbit
Rabbit
Goat
Rabbit
Rabbit
Rat
Rabbit
Rat
Rat
Rabbit
Rat
06-570, Sigma-Aldrich
ab5076, Abcam
ab18723, Abcam
LC-C402200, Nordic Biosite 
ab652, Abcam
ab19194, Abcam
019-19741, Wako Chemicals
MA5-14520, Thermo Scientific
MCA711, Bio-Rad
ab5076, Abcam
MCA2060GA, Bio-Rad
IG-851125, Nordic Biosite
X0903, DakoCytomation
P54605M, Nordic Biosite
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Secondary antibodies:
Anti-rabbit IgG
Anti-rabbit IgG
Anti-goat IgG
Anti-rat IgG
Anti-rat IgG
Tertiary antibodies:
Vectastain ABC HRP kit
Streptavidin
WESTERN BLOTTING
Primary antibodies:
Collagen Triple Helix Repeat Containing 1
Frizzled-6
Actin
Secondary antibodies:
Anti-rabbit IgG
Anti-mouse IgG
Biotinylated (1:100)
Envision+ HRP (1:200)
Biotinylated (1:100)
Biotinylated (1:200)
Biotinylated (1:100)
ABC (Avidin/Biotin)
HRP-conjugated 
streptavidin (1:200)
CTHRC1 (1:800)
FZD6 (1:1,000)
Actin (clone C4) 
(1:100,000)
HRP-conjugated (1:2,000)
HRP-conjugated (1:2,000)
Ig fraction
Ig fraction
Ig fraction
Ig fraction
Ig fraction
Ig fraction
Ig fraction
IgG1
Ig fraction
Ig fraction
Goat
Goat
Horse
Goat
Goat
Rabbit
Rabbit
Mouse
Goat
Goat
BA-1000, Vector Labs
K400311-2, Agilent
BA-9500, Vector Labs
BA-9400, Vector Labs
BA-9400, Vector Labs
PK-4000, Vector Labs
RPN1231, GE Life Sciences
ab85739, Abcam
ab229663, Abcam
MAB1501, Merck Life Science
P044801-2, Agilent
P044701-2, Agilent
Table 3. HPLC analysis of monoamines
 P-value TNF+/+ TNF-/-
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Mean pmol/mg wet tissue ± SEM (n) Mean pmol/mg wet tissue ± SEM (n)
5-HIAA/5-HT
Prefrontal cortex 0.97 0.28 ± 0.03 (6) 0.28 ± 0.03 (5)
Occipital cortex 0.19 0.60 ± 0.07 (6) 0.81 ± 0.13 (6)
Striatum 0.07 0.63 ± 0.04 (6) 0.73 ± 0.01 (6)
Hippocampus ***0.001 0.50 ± 0.02 (6) 0.69 ± 0.04 (6)
Thalamus + Hypothalamus 0.69 0.72 ± 0.06 (6) 0.69 ± 0.02 (5)
Brainstem **0.008 0.66 ± 0.02 (6) 0.79 ± 0.03 (6)
Cerebellum *0.02 0.93 ± 0.05 (6) 1.21 ± 0.08 (6)
DOPAC/DA
Prefrontal cortex 0.17 0.89 ± 0.06 (5) 0.63 ± 0.14 (6)
Occipital cortex 0.08 0.55 ± 0.09 (6) 1.60 ± 0.66 (4)
Striatum 0.17 0.06 ± 0.00 (5) 0.07 ± 0.00 (5)
Hippocampus *<0.05 1.65 ± 0.41 (5) 4.05 ± 1.08 (3)
Thalamus + Hypothalamus 0.73 0.35 ± 0.08 (6) 0.31 ± 0.06 (5)
Brainstem **0.007 0.44 ± 0.02 (6) 0.51 ± 0.01 (6)
Cerebellum N/A N/A N/A
HVA/DA
Prefrontal cortex N/A N/A N/A
Occipital cortex *0.04 0.38 ± 0.10 (6) 1.19 ± 0.38 (4)
Striatum ****0.0001 0.09 ± 0.01 (5) 0.14 ± 0.00 (5)
Hippocampus 0.51 1.36 ± 0.55 (5) 2.18 ± 1.13 (4)
Thalamus + Hypothalamus 0.43 0.33 ± 0.07 (6) 0.45 ± 0.13 (6)
Brainstem N/A N/A N/A
Cerebellum 0.66 1.06 ± 0.20 (6) 1.24 ± 0.33 (6)
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5-HT, 5-hydroxytryptamine; 5-HIAA, 5-hydroxyindoleacetic acid; DA, dopamine; DOPAC, 3,4dihydroxyphenylacetic acid; HVA, 
homovanillic acid
Highlights
•TNF deficiency alters the spatial organization of neurogenic zones
•TNF deficiency decreases WNT signaling-related proteins
•TNF deficiency alters neuronal and microglial numbers 
•Long-term use of non-selective TNF inhibitors impair learning and memory
•Long-term use of the soluble TNF selective inhibitor XPro1595 dos not affect neurogenesis, learning and 
memory
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